What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix…
What is Immix Biopharma, Inc.'s P/E and P/B ratio?
Immix Biopharma, Inc. has a P/E ratio of -9.5 and a P/B ratio of 3.02.
What is Immix Biopharma, Inc.'s debt-to-equity ratio?
Immix Biopharma, Inc. has a debt-to-equity ratio of 0.00.
How much does Immix Biopharma, Inc. owe compared with what it owns?
Immix Biopharma, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Immix Biopharma, Inc.'s Positivity rank?
Immix Biopharma, Inc. is ranked #3,746 of 6,775 companies globally and #1,674 of 4,000 in United States on PositoAI, with a Positivity Score of 20,301.
Does Immix Biopharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Immix Biopharma, Inc..
Where can I read the latest news about Immix Biopharma, Inc.?
Recent headlines about Immix Biopharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Immix Biopharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Immix Biopharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.